Flow diagram of participant inclusion in the study in Chongqing, China.

<p>This flow diagram showed the participants included in the study and final analysis of each related outcome.</p

Lengths of different types of delay among TB patients in Chongqing, China.

<p>This figure showed lengths of patient delay (A), total detection delay (B) and delay in initiating treatment(C).</p

TB knowledge and access to TB health promotion among TB patients in Chongqing, China.

<p>This figure demonstrated current TB knowledge of TB patients (A) and access to TB health education before TB diagnosis (B).</p

Univariate analysis factors association with longer delay.

<p>Notes:</p><p>Missing data were excluded.</p><p>“—”refers this variable was not included in the logistic model for this independent variable.</p><p>PL refers to local poverty line which is 3480 RMB Yuan per year since 2010; TB refers to tuberculosis.</p><p>AFB smear status refers to Acid-Fast Bacilli (AFB) Smear status.</p

Adherence to treatment, self-reported reasons for non-adherence, and treatment supervision among TB patients in Chongqing, China.

<p>This figure presented the adherence to anti-TB treatment(A), self-reported reasons for missed dose (B), self-reported reasons for interrrupted treatment(C), self-reported reasons for lack of follow-up exam(D) and treatment supervision by HCWs of different levels(E).</p

Definitions of and relations between the different types of delay among tuberculosis patients.

<p>This figure indicates the operational definitions for patient delay, total detection delay and delay in initiating treatment. It also presented the relations of the three types of delays.</p

Demographic and clinical characteristics of the questionnaire respondents.

<p>Notes:</p><p>Missing data were excluded.</p><p>PL refers to local poverty line which is 3480 RMB Yuan per year since 2010.</p><p>TB refers to tuberculosis.</p><p>AFB smear status refers to Acid-Fast Bacilli (AFB) Smear status.</p

Additional file 1: Table S1. of Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis

Drug resistant TB and MDR-TB prevalence among new and previously treated cases of the study. Table S2. Treatment success rate of acquired drug resistant TB stratified by drug resistance patterns. (DOCX 41 kb

Incidence, onset time and seriousness of adverse drug reactions due to directly observed treatment strategy therapy in 4304 Chinese tuberculosis patients.

<p>IQR, inter-quartile range.</p>#<p>The incidence of ADR was standardized for age and gender with direct standardization using one reference population that from national TB epidemic surveillance database of 2008.</p>†<p>It was from initiation of treatment.</p>§<p>Serious ADRs were defined as any untoward medical occurrence that at any dose results in death, requires hospital admission or prolongation of existing hospital stay, results in persistent or significant disability/incapacity, or is life threatening.</p>$<p>It was the time that ADRs were found, not the exact time it happened.</p>‡<p>Nervous system disorders included auditory nerve damage, optic nerve damage, peripheral nervous damage and central nervous system damage.</p>€<p>Others included one with interstitial pneumonia and another with hypokalemia.</p>*<p>For 82 patients got two ADRs, sixteen got three and one got four, 766 cases were detected and the denominator was 4304+82+32+3 = 4421.</p

Possible risk factors for the smear results at the end of intensive phase and anti- tuberculosis outcomes at the end of consolidation phase, respectively.

<p>IQR, inter-quartile range.</p>*<p>For the data of 51 patients missed, 4253 patients’ data were analyzed.</p>#<p>For the data of 16 patients missed, 4288 patients’ data were analyzed. Successful outcomes defined as the completion of treatment and patients being cured. Unsuccessful outcomes defined as treatment failure, default and death because of ADRs due to DOTS therapy.</p